AlphAIalphai — Financial news for AI agents
stocktitan.netJUL 316 min read$CL

Colgate keeps 2026 sales outlook, lifts non-GAAP EPS growth

Colgate-Palmolive (NYSE:CL) reported 2Q 2026 results. Net sales rose 4.9% and organic sales rose 2.4%. GAAP EPS fell 5%, while base business EPS increased to $0.99. For full-year 2026, the company kept net sales and GAAP EPS guidance, updated gross margin to flat and raised non-GAAP (base business) EPS growth to mid-single digits.

Original reporting
stocktitan.net
Published Jul 31, 2026, 10:58 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 31, 2026, 4:55 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefEarnings
Primary signal
$CL
Bullish
medium confidence
Mentioned
$CL
Relevance
7/10
alphai data visualization · based on stocktitan.net
Decision brief

The 30-second read

$CLBullishMed
01

Why it matters

Traders can update 2026 earnings expectations based on the revised non-GAAP EPS growth outlook and the shift to roughly flat gross profit margin versus previously down.

02

Market read

A same-day guidance update provides a concrete earnings re-rating input for CL, especially via non-GAAP Base Business EPS growth and margin expectations.

03

What to watch

Lower private label pet food sales impact is explicitly noted, and the guidance update hinges on advertising and margin stability rather than a major demand acceleration.

Relevance 7/10Novelty 6/10Timing: full-year 2026 guidance update reported pre-market today

Background

Colgate reported 2Q 2026 results and reiterated sales guidance while updating gross profit margin and Base Business EPS growth for full-year 2026.

Company-level read

Ticker impact

$CLBullishMedium confidence
Context

Colgate kept full-year 2026 net sales and updated gross margin and Base Business EPS guidance, lifting non-GAAP EPS growth to mid-single digits.

Expected impact

Moderate upside bias for CL as traders reprice 2026 Base Business EPS growth expectations.

Evidence & confidence

The article explicitly updates 2026 non-GAAP (Base Business) EPS growth to mid-single-digit and revises gross profit margin expectations to roughly flat, which are direct earnings drivers.

Market effects

Sector

Signals resilience in oral care and personal care demand, with pet nutrition volatility partially offset by portfolio strength.

Regional

No specific region-level guidance changes disclosed beyond broad worldwide organic growth commentary.

Global

Global consumer staples demand and FX sensitivity remain key swing factors, but the company reiterates sales growth range.

Counterpoint

What could challenge this read

The guidance still assumes volatile conditions and organic sales growth is only 1% to 4%, so upside may be limited if volumes weaken again.

Key entities

  • company
    Colgate-Palmolive Company

    Announced 2Q 2026 results and updated full-year 2026 guidance, including mid-single-digit Base Business EPS growth.

Read at source← All news

Also covered by

2 outlets

Related articles

AUG 4
$CLMed

Colgate-Palmolive Reaffirms Sales Forecast On Weak Demand

Colgate-Palmolive reaffirmed its annual net sales forecast despite a quarterly rise, citing weak North America demand. In the quarter ended June 30, net sales rose 4.9% to $5.36 billion and adjusted EPS was 99 cents. North America organic sales fell 3%, with volumes down 3.9%. The company expects 2026 adjusted earnings growth in mid-single digits and warned tariffs could offset refunds.

checkout.ie3 min
AUG 3
$CLMed

Colgate-Palmolive: Base Business EPS Increases 8% As Gross Margin Expands 140 Basis Points

Colgate-Palmolive reported Q2 2026 Base Business diluted EPS up 8% to $0.99 from $0.92, driven by 140 bps gross-margin expansion to 61.5% and higher organic sales. Reported diluted EPS fell 5% to $0.86 due to $129m pretax charges tied to its Strategic Growth and Productivity Program. Net sales rose 4.9% to $5.36b. Full-year organic outlook 1% to 4%; Base Business EPS expected mid-single-digit growth.

pulse2.com4 min
JUL 31
$CLMed

Colgate-Palmolive Q2 Earnings Call Highlights

Colgate-Palmolive (NYSE:CL) CFO Stan Sutula said Q2 material costs were slightly below expectations due to higher raw-material costs offset by tariff refunds, with no meaningful additional refunds expected. Management now expects full-year gross margin roughly flat, and warned second-half raw-material and tariff costs will be higher. It plans elevated ad spending and North America share recovery; Hill’s organic sales rose 4% excluding discontinued private-label.

yahoo.com4 min
JUL 31
$CLHighAI 9/10

Colgate-Palmolive Q2 2026 slides: strong results fuel raised guidance

Colgate-Palmolive (NYSE:CL) reported Q2 2026 results on July 31. Net sales rose 4.9% to $5.36B and organic sales grew 2.4%. Base EPS increased 8% and free cash flow rose 18% YoY to $1.5B YTD. The company raised 2026 guidance, including flat gross margin outlook and higher EPS growth, and projected $350M to $550M pre-tax charges for its 2030 program.

investing.com6 min
JUL 31
$CLMed

Colgate-Palmolive Lifts FY26 Adj. Earnings View, Despite Weak Q2 Profit; Stock Down

Colgate-Palmolive reported Q2 net earnings of $693 million, down from $743 million a year earlier, with EPS falling to $0.86 from $0.91. Net sales rose to $5.361 billion. The company confirmed FY2026 outlook and raised Base Business EPS growth to mid-single-digit from low- to mid-single-digit, and expects gross margin roughly flat. Shares were down about 2.78% premarket.

finanznachrichten.de4 min